Escherichia coli K5 produces heparosan and sheds it into the growth medium in a temperature dependent manner. The shedding is believed to be controlled, at least in part, by enzyme action on the cell-associated capsular polysaccharide, heparosan. One candidate enzyme in such shedding is eliminase. The eliminase gene (elmA) was deleted from the genome of E. coli K5 and its effect on secreted and cell-associated heparosan was investigated. Deletion of the eliminase gene resulted in a significant reduction in heparosan shedding into the medium and heparosan content in the capsule of the cells, indicating its pivotal role in heparosan synthesis and shedding by E. coli K5.
N-Acetyl heparosan (heparosan), the capsular polysaccharide of Escherichia coli O10:K5:H4 (ATCC 23506) (E. coli K5), is similar to heparin, with a higher acetyl content. Since it lacks sulfation and iduronic acid residues, heparosan possesses no antithrombin III binding-site (Linhardt, 2003) . Heparosan consists of repeating disaccharide units comprised of [→4) ␤-d-glucuronic acid (GlcA) (1 → 4) ␣-d-N-acetyl-glucosamine (GlcNAc) (1→] n (Wang et al., 2010) . Because of its polysaccharide similarity to heparin, heparosan is a promising starting material for the production of heparin by chemo-enzymatic synthesis (Masuko and Linhardt, 2012; Karst and Linhardt, 2003; Xu et al., 2012) . Indeed, the synthesis and shedding of large amounts of heparosan by E. coli K5 is essential for the production of bioengineered heparin for potential use as a replacement of the animal-sourced drug (Wang et al., 2010) .
The biosynthesis of heparosan in E. coli K5 involves formation of two key metabolic intermediates, UDP-glucose and UDP-Nacetyl-glucosamine, formed by kfiD. This is followed by a series of biotransformations catalyzed by enzymes encoded by two open reading frames, kfiA and kfiC, to synthesize heparosan (Hodson et al., 2000) . Heparosan is synthesized in the cytosol, transferred outside the cell by an ABC transporter-dependent mechanism (Whitfield and Roberts, 1999; Whitfield, 2006) , and the reducing end is believed to be attached to a phosphatidic acid residue. Two enzymes that have been implicated in the shedding of heparosan by E. coli K5 are K5 lyase (KflA), from the K5A bacteriophage (Clarke et al., 2000) and eliminase (ElmA), from the elmA gene in the E. coli K5 genome (Legoux et al., 1996) . These lyases display endo-␤-eliminase activity, resulting in a 4,5-unsaturated uronic acid ( UA) moiety at the non-reducing end of the heparosan chain. In the present work elmA was deleted to obtain the deletion clone, elmA. The effect of eliminase gene deletion on the production and secretion of heparosan was thus investigated and compared with that of the wild-type strain. Legoux et al. (1996) previously investigated eliminase by focusing on cloning and overexpression of the enzyme in E. coli K-12 RR1; however, the specific role of eliminase on the heparosan producing strain, E. coli K5, remains unknown. Therefore, we endeavored to elucidate the role of the elmA gene product on heparosan production and shedding from E. coli K5.
Gene deletion was achieved using the Quick & Easy E. coli Gene Deletion Kit (B-Bridge International, Inc., Cupertino, CA), and elmA gene deletion was confirmed by PCR ( Fig. 1 ). E. coli K5 and E. coli K5 ( elmA) were grown in LB medium and the undiluted supernatant was applied to a gradient PAGE gel (4-15%) ( Fig. 1 ), which revealed significant reduction in levels of heparosan shedding by E. coli ( elmA). Indeed, no supernatant heparosan was observed in gels stained with Alcian blue, suggesting that eliminase plays a key role in shedding of heparosan from the cells. All further analysis was done using size exclusion chromatography (SEC), since it was not dependent on charge density. Growth was also switched to M9 medium (Sambrook and Russell, 2001 ) to increase heparosan purity, as LB has been shown previously to generate more impurities (Wang et al., 2010) .
Prior to SEC analysis, supernatant heparosan was concentrated 10-fold using a 3 kDa MWCO centrifugal concentrator, filtered through a 0.22-m filter, and applied to a TSKgel G4000-PWxl SEC column (Tosoh Biosciences, Grove City, OH, USA) for analysis. Cellassociated heparosan, concentrated 33-fold when extracted from cell pellets using Tris buffer containing Triton X-100 and sodium deoxycholate, was filtered prior to analysis. Samples were not purified further, since this could result in loss of heparosan. Using a calibration curve and a heparosan standard (10 mg/ml), SEC postrun analysis was performed to determine heparosan concentration, M N , M W , polydispersity (Table 1) . SEC results confirmed a reduction in supernatant heparosan levels, with a 50% drop in concentration of heparosan detected in the medium from the E. coli K5 ( elmA) strain. Deletion of elmA resulted in a reduction in supernatant (Table 1 ). In the case of cell-associated heparosan, there was ca. 60% drop in heparosan concentration with the elmA mutant. Deletion of elmA also caused a reduction in M N (32,940-21,160 Da), and M W (64,390-45,350 Da), and a slight increase in polydispersity (1.95-2.14) in the cell-associated heparosan when compared to wild-type E. coli K5 (Table 1) .
These observations suggest that deletion of elmA may result in feedback inhibition in the heparosan synthetic pathway, thereby causing a reduction in heparosan production and a reduction in chain elongation for cell-associated and shed heparosan. Indeed, the total heparosan production by the deletion strain was ca. 45% of that of the wild-type E. coli K5. These findings are in agreement with the suggestion by Roberts and coworkers that eliminase may play a regulatory role in capsule synthesis (Clarke et al., 2000) , and promoting the accumulation of heparosan.
Not all K5 strains contain eliminase, PCR analysis indicated that E. coli Nissle 1917 did not possess the gene for eliminase (Fig. 1) and, thus, this strain was used for comparison. Interestingly, SEC analysis indicated that supernatant heparosan produced by E. coli Nissle 1917 exhibited greater similarity to E. coli K5 ( elmA) than wildtype E. coli K5. Thus, longer heparosan chains in the supernatant of wild-type E. coli K5 fermentation may indeed be due to eliminase, while the intermediate-length chains obtained with E. coli K5 ( elmA) and E. coli Nissle 1917 may be due to one or more other, as yet unidentified, enzymes.
E. coli Nissle 1917 was found to generate higher levels of heparosan in the supernatant, producing 0.25 mg/ml heparosan (250 mg/g cells) as compared to 0.10 mg/ml (100 mg/g cells) generated by wild-type E. coli K5. It may be that eliminase further degrades heparosan once shed, leaving mainly unreacted high molecular weight heparosan and small oligosaccharides and disaccharides; a hypothesis supported by the ability of eliminase to degrade heparosan in vitro (Fig. 2 ). An alternative hypothesis is that E. coli Nissle 1917 possesses a more effective mechanism for heparosan shedding, generating heparosan of lower polydispersity, a Conversely, the profile of cell-associated heparosan extracted from E. coli Nissle 1917 resembled that of wild-type E. coli K5 (Table 1) , although E. coli Nissle 1917 produced significantly less cell-associated heparosan (50%) than wild-type E. coli K5, suggesting that the presence of eliminase results in upregulation of capsular heparosan production to cope with the demands of eliminase. This could explain the relatively higher ratio of cell-associated heparosan to supernatant heparosan in E. coli K5 compared with E. coli K5 ( elmA) and E. coli Nissle 1917. The variation in capsule thickness could also explain why E. coli K5 is an opportunistic pathogen and E. coli Nissle 1917 is a probiotic strain, since E. coli K5 would more likely be prone to biofilm formation and E. coli Nissle 1917 would likely be motile, as suggested by Zorraquino et al. (2013) .
In conclusion, deletion of the gene encoding eliminase from the genome of E. coli K5 resulted in a dramatic change in the shedding and physical characteristics of E. coli K5 heparosan, with significant reduction in accumulation of heparosan in the cell capsule and in the culture supernatant.
